PL1617834T3 - Kompozycja farmaceutyczna zawierająca mleczan i jej zastosowania - Google Patents

Kompozycja farmaceutyczna zawierająca mleczan i jej zastosowania

Info

Publication number
PL1617834T3
PL1617834T3 PL04722501T PL04722501T PL1617834T3 PL 1617834 T3 PL1617834 T3 PL 1617834T3 PL 04722501 T PL04722501 T PL 04722501T PL 04722501 T PL04722501 T PL 04722501T PL 1617834 T3 PL1617834 T3 PL 1617834T3
Authority
PL
Poland
Prior art keywords
lactate
potassium
pharmaceutical composition
lactic acid
composition containing
Prior art date
Application number
PL04722501T
Other languages
English (en)
Inventor
Xavier M Leverve
Mustafa Iqbal
Original Assignee
Innogene Kalbiotech Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogene Kalbiotech Pte Ltd filed Critical Innogene Kalbiotech Pte Ltd
Publication of PL1617834T3 publication Critical patent/PL1617834T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
PL04722501T 2003-05-01 2004-03-22 Kompozycja farmaceutyczna zawierająca mleczan i jej zastosowania PL1617834T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ID20030213 2003-05-01
PCT/SG2004/000066 WO2004096204A1 (en) 2003-05-01 2004-03-22 Lactate containing pharmaceutical composition and uses thereof
EP04722501A EP1617834B1 (en) 2003-05-01 2004-03-22 Use of a pharmaceutical composition containing lactic acid or lactate and potassium for treating brain edema or brain injury

Publications (1)

Publication Number Publication Date
PL1617834T3 true PL1617834T3 (pl) 2007-02-28

Family

ID=33397627

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04722501T PL1617834T3 (pl) 2003-05-01 2004-03-22 Kompozycja farmaceutyczna zawierająca mleczan i jej zastosowania

Country Status (30)

Country Link
US (1) US20080125488A1 (pl)
EP (2) EP1759695A1 (pl)
JP (1) JP5037937B2 (pl)
KR (1) KR101076059B1 (pl)
CN (1) CN1777416B (pl)
AR (1) AR043670A1 (pl)
AT (1) ATE340568T1 (pl)
AU (1) AU2004233904B2 (pl)
BR (1) BRPI0409867A (pl)
CA (1) CA2523740C (pl)
CY (1) CY1105880T1 (pl)
DE (1) DE602004002585T2 (pl)
DK (1) DK1617834T3 (pl)
EA (2) EA013846B1 (pl)
ES (1) ES2274438T3 (pl)
IL (1) IL171721A (pl)
MA (1) MA27845A1 (pl)
MX (1) MXPA05011532A (pl)
MY (1) MY140382A (pl)
NO (1) NO20055652L (pl)
NZ (1) NZ543201A (pl)
PL (1) PL1617834T3 (pl)
PT (1) PT1617834E (pl)
SG (1) SG160217A1 (pl)
SI (1) SI1617834T1 (pl)
TN (1) TNSN05275A1 (pl)
TW (1) TWI290045B (pl)
UA (1) UA86937C2 (pl)
WO (1) WO2004096204A1 (pl)
ZA (1) ZA200509684B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007371A4 (en) * 2006-04-03 2009-07-22 Innogene Kalbiotech Pte Ltd LACTAT AND CALCIUM-CONTAINED PHARMACEUTICAL COMPOSITION AND ITS USES
BRPI0809330B8 (pt) 2007-03-30 2021-05-25 Laccure Ab uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
KR20120015295A (ko) * 2009-03-26 2012-02-21 풀매트릭스 인코퍼레이티드 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형
JP5671001B2 (ja) 2009-03-26 2015-02-18 パルマトリックス,インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
EP4008326A1 (en) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
ES2396650B2 (es) * 2011-07-21 2013-07-16 Universidad Complutense De Madrid Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal.
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
ES2604855T3 (es) * 2012-08-01 2017-03-09 Purac Biochem Bv Polvo de lactato y procedimiento de preparación del mismo
US9232815B2 (en) 2012-10-25 2016-01-12 Run Them Sweet, LLC Blood lactate range targets and nutritional formulations and protocols to support patients
US9897609B2 (en) 2012-10-25 2018-02-20 Run Them Sweet, LLC Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs
US9557334B2 (en) 2012-10-25 2017-01-31 Run Them Sweet Llc Formulations and methods to provide nutrition to human and other patients
EP2754356A1 (en) 2013-01-15 2014-07-16 Purac Biochem N.V. Improved nisin production process
EP2769630B1 (en) 2013-02-26 2016-04-27 Purac Biochem N.V. Improved nisin production process
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
WO2015182815A1 (ko) * 2014-05-26 2015-12-03 한국생명공학연구원 Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물
EP3481216B2 (en) 2016-07-07 2024-03-06 DSM IP Assets B.V. Process for obtaining a rapeseed protein isolate and protein isolate thereby obtained
US10124021B2 (en) * 2016-12-23 2018-11-13 Andrew L. Gostine Intravenous fluid
EP3920846A4 (en) * 2019-02-06 2022-11-09 The Board and Trustees of the Leland Stanford Junior University BIOLOGICALLY MODIFIED VASCULAR GRAPES FOR IMPROVED OUTCOMES IN BYPASS SURGERY
US20230113843A1 (en) * 2020-01-24 2023-04-13 Daniel Q. Barkey Compositions and methods for weight loss
CN119013010A (zh) * 2021-12-16 2024-11-22 艾维尔勒斯生物公司 用于治疗慢性肺病的可吸入或可摄入的乳酸组合物
CN116531358A (zh) * 2023-06-06 2023-08-04 中国医科大学附属第一医院 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用
EP4502147A1 (en) 2023-07-31 2025-02-05 M2Rlab SL Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502274A (ja) * 1985-12-18 1988-09-01 ビ−チ,リチヤ−ド エル L↓−乳酸および/またはピルビン酸アニオンを用いた流体式治療法
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248507A (en) * 1991-05-31 1993-09-28 Board Of Regents, The University Of Texas System Hypertonic isochloremic formulation for circulatory shock
JPH05255092A (ja) * 1992-03-17 1993-10-05 Kyowa Hakko Kogyo Co Ltd 腸管洗浄用組成物
PT701455E (pt) * 1993-06-04 2001-09-27 Biotime Inc Solucao semelhante a plasma
US6306828B1 (en) * 1995-04-06 2001-10-23 Baxter International, Inc. Enantiomerically-enhanced nutritional energy substrates
JPH0940554A (ja) * 1995-08-03 1997-02-10 Nissho Corp グルタミンを含む輸液及びその製造方法
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
US6436444B1 (en) * 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
RU2136293C1 (ru) * 1998-08-04 1999-09-10 Открытое акционерное общество "Биохимик" Способ получения заменителя плазмы крови

Also Published As

Publication number Publication date
TWI290045B (en) 2007-11-21
NO20055652D0 (no) 2005-11-30
JP5037937B2 (ja) 2012-10-03
DK1617834T3 (da) 2007-02-05
KR20050119701A (ko) 2005-12-21
SG160217A1 (en) 2010-04-29
EP1617834A1 (en) 2006-01-25
TW200423923A (en) 2004-11-16
HK1085942A1 (en) 2006-09-08
IL171721A (en) 2012-05-31
AU2004233904A1 (en) 2004-11-11
CN1777416B (zh) 2012-11-07
EA013846B1 (ru) 2010-08-30
TNSN05275A1 (en) 2007-07-10
NZ543201A (en) 2007-05-31
MXPA05011532A (es) 2006-05-31
KR101076059B1 (ko) 2011-10-21
ATE340568T1 (de) 2006-10-15
WO2004096204A1 (en) 2004-11-11
CN1777416A (zh) 2006-05-24
ZA200509684B (en) 2007-03-28
DE602004002585D1 (de) 2006-11-09
BRPI0409867A (pt) 2006-05-16
EP1759695A1 (en) 2007-03-07
SI1617834T1 (sl) 2007-02-28
US20080125488A1 (en) 2008-05-29
ES2274438T3 (es) 2007-05-16
CA2523740A1 (en) 2004-11-11
MY140382A (en) 2009-12-31
EA200801073A1 (ru) 2008-08-29
CA2523740C (en) 2012-05-15
AU2004233904B2 (en) 2009-11-12
UA86937C2 (ru) 2009-06-10
JP2006525324A (ja) 2006-11-09
EP1617834B1 (en) 2006-09-27
PT1617834E (pt) 2007-01-31
EA200501675A1 (ru) 2006-06-30
AR043670A1 (es) 2005-08-03
NO20055652L (no) 2006-02-01
MA27845A1 (fr) 2006-04-03
EA010948B1 (ru) 2008-12-30
CY1105880T1 (el) 2011-02-02
DE602004002585T2 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
SI1617834T1 (sl) Uporaba farmacevtskega sestavka, ki vsebuje mlecno kislino ali laktat in kalij, za zdravljenje mozganskega edema in mozganske poskodbe
EP1737453A4 (en) METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
PL1673104T3 (pl) Dostarczanie związków terapeutycznych do mózgu i do innych tkanek
EP1638605A4 (en) DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE
HUS1500021I1 (hu) 1,2,4-oxadiazol-benzoesav vegyületek és alkalmazásuk nonszensz szupresszióra és a betegség kezelésére
AU2003300939A8 (en) Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
ZA200610353B (en) Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmenthanones
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
IL207559A0 (en) Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
WO2008105088A1 (ja) 脊髄損傷治療薬剤
MY147404A (en) Process for preparation of n-benzoyl-staurosporine
EP1753425A4 (en) THERAPEUTIC AGENT COMPRISING A NICOTINIC ACID OR DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER
PL378197A1 (pl) Pochodne kwasów indenokarboksylowych oraz ich zastosowanie do leczenia i zapobiegania cukrzycy i dyslipidemii
IL179039A0 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
TWI345980B (en) Pharmaceutical compositions for preventing or treating injuries of brain tissue
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject
AU2003266621A8 (en) Medicinal composition for treatment for or prevention of visceral pain
GB0304871D0 (en) Formulation for treatment of paralizing pain stiffness
ZA200610028B (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
AU2004907310A0 (en) PGEI Composition for treatment of vascular disease and or vascular injury
HK1101801A (en) Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmethanones
GB0325259D0 (en) Therapeutic agents for the treatment of bone conditions
GB0310463D0 (en) Therapeutic agents for the treatment of bone conditions
TWI341204B (en) Composition and method for prevention and treatment of alzheimer's disease